Meta Platforms Beats The Man, Again - We Move To Accumulate Rating

Cestrian Capital Research Investing Group Leader Follow Summary Meta Platforms settled child-harm lawsuits, agreeing to pay ~$18 billion over a decade, with limited impact on the stock. META has already experienced a 35% peak-to-trough drop, with recent lows double-tested and sentiment remaining weak. We believe the stock has a favorable risk/reward setup, rating META 'Accumulate' between $516 and $677, with a suggested stop just below $516. Potential upside targets are $835 (100% Fibonacci extension) and $1030 (1.618 extension), offering a 4:1 upside/downside ratio. Looking for a helping hand in the market? Members of Growth Investor Pro get exclusive ideas and guidance to navigate any climate. Learn More » DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by, any UK recipients. Nothing in this note is intended to be investment advice, nor should it be relied This article was written by Cestrian Capital Research 17.61K Followers Follow Cestrian Capital Research, Inc. is an independent, SEC-registered investment research firm (CRD # 291803) led by CEO Alex King, a professional investor with three decades of experience across venture capital, private equity and public markets.Cestrian publishes ratings, price targets, stop levels and accumulation zones on a sector-diverse universe of US-listed stocks and ETFs, spanning technology and semiconductors, space and defense, drones, energy, and biotechnology and pharmaceuticals, alongside index and sector ETFs, options, and crypto and macro. Covered names range from Nvidia (NVDA), Rocket Lab (RKLB) and Tesla (TSLA) to Moderna (MRNA), Pfizer (PFE), Merck (MRK) and BioNTech (BNTX). Research is also distributed on the Bloomberg Terminal.The team pairs fundamental analysis with volume/price and market-structure work, plus the SignalFlow family of quantitative signal services. A Daily Market Review is published every US trading day.Cestrian's full research service on Seeking Alpha is Growth Investor Pro, which includes the live GIP Portfolio, price alerts, the Daily Review, a weekly live webinar and 24/7 chat.Ratings are the dated opinion of Cestrian Capital Research, Inc., are subject to change without notice, and are not investment advice. Learn More. Analyst’s Disclosure: I/we have a beneficial long position in the shares of MAGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Cestrian Capital Research, Inc staff personal accounts hold long position(s) in MAGS. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.